Determination of nicainoprol, a new antiarrhythmic agent, in human plasma and urine by high-performance liquid chromatography.
A new method for the determination of nicainoprol in human plasma and urine has been developed. Nicainoprol and p-chlorodisopyramide as the internal standard are extracted into dichloromethane under basic conditions, and then evaporated to dryness. A reconstituted aliquot is injected onto a cyanopropyl column with an automatic high-performance liquid chromatographic system and quantitated using ultraviolet detection at 250 nm. The whole system-elapsed time to analyse a sample is ca. 10 min, and the detection limit using 1 ml of plasma is 15 ng/ml. Preliminary plasma and urinary concentration-time data from a healthy subject following an oral nicainoprol administration are reported. The assay method presented appears to be selective, and is of sufficient sensitivity, precision and accuracy to be applicable to the study of the pharmacokinetic behaviour of nicainoprol in humans.
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000032:analysis* / Q000097:blood / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D006801:Humans; D007700:Kinetics; D008297:Male; D011412:Propanolamines / Q000032:analysis* / Q000097:blood / Q000652:urine
D000889:Anti-Arrhythmia Agents; D011412:Propanolamines; C047768:nicainoprol